Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
Vaxcyte (PCVX) has scheduled a webcast and conference call for March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. The study evaluates the safety, tolerability, and immunogenicity of VAX-24, their 24-valent pneumococcal conjugate vaccine candidate, compared to Prevnar 20® in healthy infants.
VAX-24 is designed to prevent invasive pneumococcal disease (IPD). The presentation will be accessible via phone (800-445-7795 domestic, 785-424-1699 international) with conference ID PCVX0331, and through a live webcast on Vaxcyte's investor relations website. The webcast recording will remain available for 30 days after the event.
Vaxcyte (PCVX) ha programmato un webcast e una conferenza telefonica per il 31 marzo 2025, alle 8:00 ora orientale, per presentare i risultati preliminari dello studio di Fase 2 VAX-24 sui neonati. Lo studio valuta la sicurezza, la tollerabilità e l'immunogenicità di VAX-24, il loro candidato vaccinale coniugato pneumococcico a 24 valenti, rispetto a Prevnar 20® nei neonati sani.
VAX-24 è progettato per prevenire la malattia pneumococcica invasiva (IPD). La presentazione sarà accessibile tramite telefono (800-445-7795 nazionale, 785-424-1699 internazionale) con l'ID conferenza PCVX0331, e attraverso un webcast in diretta sul sito web delle relazioni con gli investitori di Vaxcyte. La registrazione del webcast rimarrà disponibile per 30 giorni dopo l'evento.
Vaxcyte (PCVX) ha programado un webcast y una llamada de conferencia para el 31 de marzo de 2025, a las 8:00 a.m. hora del Este, para presentar los resultados preliminares del estudio de Fase 2 VAX-24 en infantes. El estudio evalúa la seguridad, tolerabilidad e inmunogenicidad de VAX-24, su candidato a vacuna conjugada neumocócica de 24 valencias, en comparación con Prevnar 20® en infantes sanos.
VAX-24 está diseñado para prevenir la enfermedad neumocócica invasiva (IPD). La presentación será accesible por teléfono (800-445-7795 nacional, 785-424-1699 internacional) con el ID de conferencia PCVX0331, y a través de un webcast en vivo en el sitio web de relaciones con inversores de Vaxcyte. La grabación del webcast estará disponible durante 30 días después del evento.
Vaxcyte (PCVX)는 2025년 3월 31일 동부 표준시 기준 오전 8시에 VAX-24 유아 2상 연구의 주요 결과를 발표하기 위한 웹캐스트와 전화 회의를 예정하고 있습니다. 이 연구는 VAX-24, 24가 폐렴구균 결합 백신 후보의 안전성, 내약성 및 면역원성을 Prevnar 20®와 비교하여 건강한 유아에서 평가합니다.
VAX-24는 침습성 폐렴구균 질환(IPD)을 예방하기 위해 설계되었습니다. 발표는 전화(800-445-7795 국내, 785-424-1699 국제)와 Vaxcyte의 투자자 관계 웹사이트에서 실시간 웹캐스트를 통해 접근할 수 있습니다. 웹캐스트 녹화는 이벤트 후 30일 동안 이용 가능합니다.
Vaxcyte (PCVX) a prévu un webcast et une conférence téléphonique pour le 31 mars 2025 à 8h00, heure de l'Est, afin de présenter les résultats préliminaires de l'étude de Phase 2 VAX-24 chez les nourrissons. L'étude évalue la sécurité, la tolérance et l'immunogénicité de VAX-24, leur candidat vaccin conjugué pneumococcique à 24 valences, par rapport à Prevnar 20® chez des nourrissons en bonne santé.
VAX-24 est conçu pour prévenir les maladies pneumococciques invasives (IPD). La présentation sera accessible par téléphone (800-445-7795 national, 785-424-1699 international) avec l'ID de conférence PCVX0331, et via un webcast en direct sur le site web des relations avec les investisseurs de Vaxcyte. L'enregistrement du webcast restera disponible pendant 30 jours après l'événement.
Vaxcyte (PCVX) hat für den 31. März 2025 um 8:00 Uhr Eastern Time eine Webcast- und Telefonkonferenz angesetzt, um die vorläufigen Ergebnisse der VAX-24 Phase-2-Studie bei Säuglingen zu präsentieren. Die Studie bewertet die Sicherheit, Verträglichkeit und Immunogenität von VAX-24, ihrem 24-valent pneumokokkenkonjugierten Impfstoffkandidaten, im Vergleich zu Prevnar 20® bei gesunden Säuglingen.
VAX-24 ist darauf ausgelegt, invasive pneumokokkale Erkrankungen (IPD) zu verhindern. Die Präsentation ist telefonisch (800-445-7795 national, 785-424-1699 international) mit der Konferenz-ID PCVX0331 sowie über einen Live-Webcast auf der Investor-Relations-Website von Vaxcyte zugänglich. Die Aufzeichnung des Webcasts bleibt 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.
To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international) and refer to conference ID PCVX0331. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
What are the key details of Vaxcyte's (PCVX) upcoming VAX-24 Phase 2 results presentation?
What is the purpose of Vaxcyte's VAX-24 Phase 2 clinical trial in infants?
How many pneumococcal serotypes does Vaxcyte's VAX-24 vaccine candidate target?
How long will the VAX-24 Phase 2 results webcast be available on Vaxcyte's website?
